rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Fifty-six distinct uncommon <i>EGFR</i> mutations other than L858R, exon19del, exon20ins, or T790M were identified in 18.9% of patients with <i>EGFR</i>-mutant NSCLC.
|
30902917 |
2019 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Finally, we evaluated the concordance between plasma and tumour tissues by simultaneously detecting EGFR L858R by ddPCR and LNA-dPNA PCR clamp in 132 tissues and matched plasma samples from patients with NSCLC.
|
30663747 |
2019 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
First generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (gefitinib and erlotinib) demonstrate excellent clinical efficacy for NSCLC patients carrying EGFR oncogenic mutations (L858R, del exon 19 deletions between amino acids 746 and 750).
|
26968253 |
2016 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
First- and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung cancers (NSCLCs) that harbor sensitizing EGFR mutations (i.e. exon 19 deletions or L858R).
|
26943236 |
2016 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
First-generation <i>EGFR</i> TKIs, binding competitively and reversibly to the ATP-binding site of the <i>EGFR</i> tyrosine kinase domain, have resulted in a significant improvement in outcome for NSCLC patients with activating <i>EGFR</i> mutations (L858R and Del19).
|
28149837 |
2016 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Further on, we performed a retrospective evaluation of seven patients with advanced EGFR-mutated (exon 19 deletions and L858R) NSCLC that were given erlotinib at 25 mg/d as their first EGFR TKI.
|
20512075 |
2010 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Here we report a case of emergent <i>MET</i> amplification detected in a tumor sample from a patient with NSCLC harboring EGFR L858R mutation after disease progression on erlotinib.
|
30881166 |
2019 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Here we report efficacy and safety data of an Asian subset of the phase III FLAURA trial (NCT02296125), which compares osimertinib with standard of care (SoC) EGFR tyrosine kinase inhibitors (TKIs) in patients with previously untreated advanced NSCLC with tumors harboring exon 19 deletion (Ex19del)/L858R EGFR TKI-sensitizing mutations.
|
30240852 |
2019 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Here, we report a case of an advanced chemotherapy-resistant NSCLC, harboring a novel HER3(V855A) somatic mutation homologous to the EGFR(L858R)activating mutation.
|
26689995 |
2016 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Here, we show that L858R and deletion mutant EGFR proteins found in NSCLC interact with the chaperone and are sensitive to degradation following Hsp90 inhibition.
|
16024644 |
2005 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
HRMA is a precise method for detecting DEL and L858R mutations and is useful for predicting clinical outcomes in patients with advanced NSCLC treated with gefitinib.
|
17875767 |
2007 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells.
|
26375053 |
2015 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer.
|
28357677 |
2017 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Importantly, the TKI resistance that emerges even in cigarette smoke-exposed L858R EGFR-expressing NSCLC cells could be eliminated with Src inhibition.
|
23686837 |
2013 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In 77 TTNAs (71.3.%) that were positive for non-small cell lung cancer, the variant in exon 21 (the missense mutation at codon 858, L858R) and the deletion in exon 19 (in frame deletion at codons 747-749) of the EGFR gene, and the point mutation in exon 2 of KRAS were investigated with HRM assay using sequencing as the reference "gold standard".
|
19640859 |
2009 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In non-small cell lung cancer (NSCLC), the association between common EGFR mutations (Del EX19/L858R) with EGFR tyrosine kinase inhibitors (EGFR-TKIs) has been well established.
|
25558790 |
2015 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In our case, a non-small cell lung cancer patient developed intrinsic EGFR-TKI resistance and was then confirmed to simultaneously harbor an L858R mutation and ROS1 rearrangement.
|
30775851 |
2019 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In our initial study, we revealed that the dominant EGFR mutations such as L858R and T790M could be detected in Non Small Cell Lung Cancer (NSCLC) patients with low CTC counts.
|
28560679 |
2017 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In particular, a number of EGFR mutants that demonstrate ligand-independent signaling are common in non-small cell lung cancer (NSCLC), including kinase domain mutations L858R (also called L834R) and exon 19 deletions (e.g., ΔL747-P753insS), which collectively make up nearly 90% of mutations in NSCLC.
|
26337388 |
2015 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In patients with epidermal growth factor receptor (EGFR)-mutated, advanced, non-small cell lung cancer (NSCLC), common gefitinib-sensitive EGFR mutations that predict a greater response to therapy include the exon 19 deletion and L858R point mutation.
|
28168310 |
2017 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In the entire assessable population of 4465 EGFR-mutant NSCLC patients, significant interactions with PFS were found for gender (males vs. females; pooled ratio of the PFS-HRs = 1.2; 95% CI 1.12-1.56), smoking history (smokers vs. non-smokers; pooled ratio of the PFS-HRs = 1.26; 95% CI 1.05-1.51), and type of EGFR mutation (patients with exon 21 L858R mutation vs. exon 19 deletion; pooled ratio of the PFS-HRs = 1.39; 95% CI 1.18-1.63).
|
31466227 |
2019 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In the phase III FLAURA study, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved progression-free survival (PFS) versus standard-of-care (SoC) EGFR-TKI (gefitinib or erlotinib) in patients with previously untreated EGFR (exon 19 deletion or L858R) mutation-positive advanced non-small cell lung cancer (NSCLC).
|
30659024 |
2019 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-positive (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a standard EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily).
|
29151359 |
2018 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In this international, multicentre, randomised, open-label, phase 3 study (ARCHER 1050), we enrolled adults (aged ≥18 years or ≥20 years in Japan and South Korea) with newly diagnosed advanced NSCLC and one EGFR mutation (exon 19 deletion or Leu858Arg) at 71 academic medical centres and university hospitals in seven countries or special administrative regions.
|
28958502 |
2017 |
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In this open-label, phase II study, patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations (either exon 19 deletion or L858R point mutation) were assigned randomly to receive pemetrexed (500 mg/m(2)) and carboplatin (AUC = 5), administered every 21 days for 4 cycles, followed with or without gefitinib (250 mg/day) for 6 months.
|
24585406 |
2014 |